[go: up one dir, main page]

AR054393A1 - Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. - Google Patents

Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.

Info

Publication number
AR054393A1
AR054393A1 ARP060102490A ARP060102490A AR054393A1 AR 054393 A1 AR054393 A1 AR 054393A1 AR P060102490 A ARP060102490 A AR P060102490A AR P060102490 A ARP060102490 A AR P060102490A AR 054393 A1 AR054393 A1 AR 054393A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
alkyl
group
benzo
amino
Prior art date
Application number
ARP060102490A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR054393A1 publication Critical patent/AR054393A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Composiciones farmacéuticas que los contienen y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de serotonina 5-HT noradrenalina (NA) y dopamina (DA). Reivindicacion 1: La presente se refiere a un compuesto representado por la formula general (1) en la cual U es O o S; R1-R2 son seleccionados independientemente del grupo que consiste en H, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, y cicloalqu(en)il C3-8-alqu(en/in)ilo C1-6, o R1 y R2 forman conjuntamente con el N al que están unidos un anillo de 4-7 miembros que no contiene ninguno o contiene un doble enlace, comprendiendo opcionalmente dicho anillo además de dicho N otro heteroátomo seleccionado de O y S; R3-R6 se seleccionan independientemente del grupo que consiste en H, halogeno, ciano, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, y cicloalqu(en)il C3-8-alqu(en/in)ilo C1-6, haloalqu(en/in)ilo C1-6, halocicloalqu(en)ilo C3-8 y halocicloalqu(en)il C3-8-alqu(en/in)ilo 1- 6; R7 se selecciona del grupo que consiste en , alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8 y cicloalqu(en)il C3-8-alqu(en/in)ilo C1-6; R8 -R11 se seleccionan independientemente del grupo que consiste en H, halogeno, ciano, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)il C3-8-alqu(en/in)ilo C1-6, haloalqu(en/in)ilo C1-6, halocicloalqu(en)ilo C3-8, halocicloalqu(en)il C3-8-alqu(en/in)ilo C1-6, nitro, amino, alqu(en/in)il C1-6-amino, di-(alqu(en/in)il C1-6)-amino, cicloalqu(en)il C3-8-amino, cicloalqu(en)il C3-8-alqu(en/in)il C1-6-amino, hidroxilo, alqu(en/in)iloxilo C1-6, cicloalqu(en)iloxilo C3-8, cicloalqu(en)il C3-8-alqu(en/in)iloxilo C1-6, alqu(en/in)il C1-6-sulfanilo, cicloalqu(en)il C3-8-sulfanilo y cicloalqu(en)il C3- 8-alqu(en/in)il C1-6-sulfanilo; m, n, o y p son independientemente 0 o 1; X se selecciona del grupo que consiste en CH2, CHR12 y CR13R14; Y se selecciona del grupo que consiste en CH2, CHR15 y CR16R17; Z se selecciona del grupo que consiste en CH2, CHR18 y CR19R20; y Q se selecciona del grupo que consiste en CH2, CHR21 y CR22R23; en donde R12-R23 se seleccionan independientemente del grupo que consiste en alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8 y cicloalqu(en)il C3-8-alqu(en/in)ilo C1-6; como la base libre o una sal del mismo.
ARP060102490A 2005-06-17 2006-06-13 Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. AR054393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500895 2005-06-17

Publications (1)

Publication Number Publication Date
AR054393A1 true AR054393A1 (es) 2007-06-20

Family

ID=37574258

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102490A AR054393A1 (es) 2005-06-17 2006-06-13 Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.

Country Status (15)

Country Link
US (2) US7534791B2 (es)
EP (1) EP1893596A2 (es)
JP (1) JP2008546680A (es)
KR (1) KR20080016655A (es)
CN (1) CN101208324A (es)
AR (1) AR054393A1 (es)
AU (1) AU2006283224A1 (es)
BR (1) BRPI0612236A2 (es)
CA (1) CA2611736A1 (es)
EA (1) EA200800073A1 (es)
IL (1) IL188063A0 (es)
MX (1) MX2007015401A (es)
NO (1) NO20080268L (es)
WO (1) WO2007023395A2 (es)
ZA (1) ZA200710884B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
JP2012512172A (ja) * 2008-12-15 2012-05-31 タイゲン バイオテクノロジー カンパニー，リミテッド ピペリジン誘導体の立体選択的合成

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803143A (en) 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) * 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (en) * 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof
GB8912971D0 (en) * 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ATE190608T1 (de) 1991-11-25 2000-04-15 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
KR100533431B1 (ko) 1995-01-23 2006-05-03 다이이치 아스비오파마 가부시키가이샤 허혈성질환에기인하는증상의완화또는치료용약제및이에유용한화합물
ATE195125T1 (de) 1995-11-06 2000-08-15 Dsm Nv Verfahren zur de-esterifikation
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4091697A (en) 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
GB9725953D0 (en) * 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
EA200101017A1 (ru) 1999-04-02 2002-04-25 Айкос Корпорейшен Ингибиторы связывания lfa-1 с icam и их использование
AU780725B2 (en) 1999-04-30 2005-04-14 Trustees Of The University Of Pennsylvania, The Spect imaging agents for serotonin transporters
MXPA02001160A (es) 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
PL355289A1 (en) 1999-10-13 2004-04-05 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
DE60011817T2 (de) 1999-12-30 2005-07-14 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
NZ519647A (en) 1999-12-30 2004-02-27 H Substituted phenyl-piperazine derivatives, their preparation and use
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
WO2001064206A2 (en) 2000-02-29 2001-09-07 Integriderm, Inc. Inhibitors of melanocyte tyrosinase as topical skin lighteners
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6455738B1 (en) 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2002015910A1 (en) 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
BR0113445A (pt) 2000-09-01 2005-04-12 Fmc Corp Composto, composição, e, método para o controle de insetos
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
DE60129148T2 (de) 2000-10-06 2008-02-28 Biocompatibles Uk Ltd., Farnham Zwitterionische polymere
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
DE60131675T2 (de) 2000-11-14 2008-11-20 Merck Patent Gmbh Neue verwendung von substanzen mit kombinierten 5-ht1a agonistischen und serotonin reuptake inhibitor-aktivitäten
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE60218037T2 (de) 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag Neue indolderivate mit affinität zum 5-ht6-rezeptor
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
HUP0401924A3 (en) 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
MXPA04006119A (es) 2001-12-21 2004-11-01 Lundbeck & Co As H Derivados aminoindano como inhibidores de la absorcion de la serotonina y de la norepinefrina.
EP1465933B1 (en) 2002-01-16 2007-08-29 Biocompatibles UK Limited Polymer conjugates
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
JP4151842B2 (ja) 2002-03-04 2008-09-17 独立行政法人科学技術振興機構 新規なホスホン酸アミド化合物、その製造方法及び用途
EP2557139B1 (en) 2002-03-29 2021-05-05 Massachusetts Institute Of Technology Light emitting device including semiconductor nanocrystals
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
CA2498946A1 (en) 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,4-substituted indoles and their use as 5-ht6 modulators
ATE362469T1 (de) 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
US20040137389A1 (en) 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US7189501B2 (en) 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
US7820753B2 (en) 2003-02-05 2010-10-26 Biocompatibles Uk Limited Block copolymers
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
US7229751B2 (en) 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
WO2005060711A2 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
DK1701940T3 (da) 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
SE528250C2 (sv) 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
US20090156471A1 (en) 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
EP1793272A4 (en) 2004-08-24 2008-01-23 Fujifilm Corp PHOTOGRAPHIC PHOTOSENSITIVE COLOR MATERIAL BASED ON SILVER HALIDE AND METHOD OF FORMING IMAGES
CA2582658A1 (en) 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd. Method for producing thioether compound
US20060135540A1 (en) 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
WO2006063606A1 (en) 2004-12-16 2006-06-22 Pirelli & C. S.P.A. Process for manufacturing a thermoplastic elastomeric material
JP4989881B2 (ja) 2004-12-28 2012-08-01 富士フイルム株式会社 有機電界発光素子
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US20060276440A1 (en) 2005-01-03 2006-12-07 An Wenqian F Treatment of inflammatory disorders
EP1867704B1 (en) 2005-03-15 2010-09-15 FUJIFILM Corporation Surface treatment method using disc-like compound, (lubricating) composition for surface treatment, and surface-treated article
US20060216546A1 (en) 2005-03-28 2006-09-28 Fuji Photo Film Co., Ltd. Organic electroluminescent element
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
DE102005037336A1 (de) * 2005-08-04 2007-02-08 Degussa Ag Kohlenstoffmaterial

Also Published As

Publication number Publication date
EP1893596A2 (en) 2008-03-05
MX2007015401A (es) 2008-03-04
NO20080268L (no) 2008-02-07
ZA200710884B (en) 2009-04-29
US20060287386A1 (en) 2006-12-21
EA200800073A1 (ru) 2008-06-30
KR20080016655A (ko) 2008-02-21
WO2007023395A2 (en) 2007-03-01
CN101208324A (zh) 2008-06-25
CA2611736A1 (en) 2007-03-01
JP2008546680A (ja) 2008-12-25
US20090192213A1 (en) 2009-07-30
IL188063A0 (en) 2008-03-20
BRPI0612236A2 (pt) 2016-11-22
US7534791B2 (en) 2009-05-19
WO2007023395A3 (en) 2007-07-12
AU2006283224A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
MX2020009928A (es) Compuestos organicos.
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
MX2020000261A (es) Nuevos compuestos.
PE20211333A1 (es) Compuestos de sulfonamidaurea novedosos
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
UY31545A1 (es) Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
MX387700B (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
UY32391A (es) Compuestos amino-heterocíclicos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
BR112013025420A2 (pt) medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento
MX2016007056A (es) Metodos para preparar compuestos de benzoquinolina.
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
CL2022003646A1 (es) Derivados de amidopirimidona
MX2017012396A (es) Derivado de anillo fusionado de 9 elementos.
AR067904A1 (es) Derivados de piperazina-amida
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CL2020001817A1 (es) Moduladores del receptor c5a
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash

Legal Events

Date Code Title Description
FA Abandonment or withdrawal